Showing 7861-7870 of 9757 results for "".
- From Tattoos to Virtual Tools: A Look at the Technology Transforming Hair Clinicshttps://practicaldermatology.com/news/from-tattoos-to-virtual-tools-a-look-at-the-technology-transforming-hair-clinics/2471548/
- Novel TYK2 Inhibitor Shows Promising Results in Phase 2 Trials for PsOhttps://practicaldermatology.com/news/Novel-TYK2-Inhibitor-Shows-Promising-Results-Phase-2-Trials-PsO/2471545/The TYK2 inhibitor ESK-001 has shown promising safety and efficacy in long-term Phase 2 trials for moderate-to-severe plaque psoriasis, Andrew Blauvelt, MD, FAAD, said in a late-breaking research presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- Cardio-Dermatology: Multidisciplinary Care Essential for Reducing Multifaceted Riskhttps://practicaldermatology.com/news/cardio-dermatology-multidisciplinary-care-essential-for-reducing-multifaceted-risk/2471287/Chronic skin conditions like psoriasis and atopic dermatitis (AD) are more than skin-deep—they carry significant risks for heart disease and require special attention, according to a compelling presentation given at Masterclasses in Dermatology 2025 in Sarasota. In her talk, Brittany Weber
- New Option for Molluscum Expected Soonhttps://practicaldermatology.com/news/New-Option-Molluscum-Expected-Soon/2471226/Perhaps the most important measure a dermatologist can take after diagnosing a patient with molluscum is to reassure them that it is not a big deal, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at Winter Clinical Hawaii 2025 in Waikoloa Village, Hawaii.
- Guselkumab Effective in Psoriasis Regardless of Prior Treatment History: Studyhttps://practicaldermatology.com/news/guselkumab-effective-regardless-of-prior-treatment-history-study/2471126/Guselkumab was effective at managing moderate-to-severe psoriasis over five years, regardless of baseline disease severity or treatment history, according to a post hoc analysis of the VOYAGE 1 and 2 trials. The study looked
- Pacific Northwest Practice Hiringhttps://practicaldermatology.com/news/Pacific-Northwest-Practice-Hiring/2471098/Clear Choice Dermatology announced it is seeking a board-certified dermatologist to work in its locations in Portland, Oregon, or Salem, Oregon. Clear Choice has 11 locations throughout Oregon and Washington. Owner and Chief Medical Officer Collin Blattner, DO, FAAD, is a member of Pra
- Phase 1 Study Begins for New Systemic for CPUOhttps://practicaldermatology.com/news/Phase-1-Study-Begins-New-Systemic-CPUO/2471095/The first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) anti-IL-31 biotherapeutic, Attovia Therapeutics announced. ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic co
- GW Earns Skin Smart Campus Recognitionhttps://practicaldermatology.com/news/GW-Earns-Skin-Smart-Campus-Recognition/2471093/The National Council on Skin Cancer Prevention recognized George Washington University as a Skin Smart Campus for its ongoing commitment to fostering a safe and healthy learning environment, with a focus on skin cancer prevention and UV safety, the university announced. The Skin Smart Camp
- Study: Newer Biologics Do Not Increase MACE/VTE Risk in PsO/PsAhttps://practicaldermatology.com/news/Study-Newer-Biologics-Do-Not-Increase-MACE-VTE-Risk-PsO-PsA/2471065/A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.<